Review of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast Enrollment
DOI10.1007/978-3-030-88658-5_9OpenAlexW4289354641MaRDI QIDQ5051094
Publication date: 18 November 2022
Published in: Emerging Topics in Statistics and Biostatistics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1007/978-3-030-88658-5_9
BOINCRMMCMClogistic regression modelBayesian logistic regression modelescalation with overdose controloncologyDTLMTDDLTBayesian optimal intervalBayesian optimal interval designBLRMBOIN12continuous reassessment methodEWOCFIHfirst-in-humanLaplan-Meierlikelihood function methodlong-term dose-limiting toxicitymaximumly tolerated dosemodified toxicity probability intervalmTPInon-tolerated doseNTDphase 2 trialR-TPIRD2Prolling-TPITITE-BOINTITE-CRMtoxicity interval-based algorithmstoxicity probability interval methodTPI
Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian inference (62F15) Reliability and life testing (62N05)
Cites Work
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
- Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial
- Robust EM Continual Reassessment Method in Oncology Dose Finding
- Design and Analysis of Phase I Clinical Trials
- Monitoring late-onset toxicities in phase I trials using predicted risks
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
This page was built for publication: Review of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast Enrollment
